PMAIP1 and triple-negative breast carcinoma: Studies have confirmed the involvement of PMAIP1 in leukemia (Shah et al., 2023), pancreatic cancer (Doffo et al., 2022), pituitary adenoma (Asuzu et al., 2022) and triple-negative breast cancer (Cirillo et al., 2023), and other cancer types.